Compare Expeditors International of Wshngtn Inc (EXPD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.04B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Expeditors International of Wshngtn Inc pays a 0.91% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| EXPD | XBI | |
|---|---|---|
Market Cap | $23.04B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $182.80 | $164.28 |
52-Week Low | $113.13 | $86.92 |
Enterprise Value | $22.57B | — |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $184.47, up 3.06% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS surging 51% to $2.03, driven by airfreight demand and customs complexity. Revenue growth accelerated to $11.07B in 2025, though net margins compressed slightly to 7.32%. Analyst sentiment remains cautious with 63.6% hold ratings, but the stock trades above the consensus price target of $181.14.
Outlook remains positive with earnings momentum and expanding AOG services, but faces risks from ocean freight contraction and valuation concerns. The current P/E of 25.8x appears stretched relative to historical levels, while institutional ownership shows mixed signals with recent reductions. Near-term performance hinges on Q3 earnings delivery against $2.12 expectations.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
